Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2013 1
2014 1
2015 1
2020 4
2021 8
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
iNKT cell-neutrophil crosstalk promotes colorectal cancer pathogenesis.
Lattanzi G, Strati F, Díaz-Basabe A, Perillo F, Amoroso C, Protti G, Rita Giuffrè M, Iachini L, Baeri A, Baldari L, Cassinotti E, Ghidini M, Galassi B, Lopez G, Noviello D, Porretti L, Trombetta E, Messuti E, Mazzarella L, Iezzi G, Nicassio F, Granucci F, Vecchi M, Caprioli F, Facciotti F. Lattanzi G, et al. Among authors: galassi b. Mucosal Immunol. 2023 Jun;16(3):326-340. doi: 10.1016/j.mucimm.2023.03.006. Epub 2023 Mar 31. Mucosal Immunol. 2023. PMID: 37004750 Free article.
Immune checkpoint inhibitor therapy for hepatocellular carcinoma.
Ramai D, Shapiro A, Facciorusso A, Bareggi C, Gambini D, Rijavec E, Tomasello G, Galassi B, Ghidini M. Ramai D, et al. Among authors: galassi b. Ann Gastroenterol. 2022 Nov-Dec;35(6):568-576. doi: 10.20524/aog.2022.0746. Epub 2022 Oct 3. Ann Gastroenterol. 2022. PMID: 36406972 Free PMC article. Review.
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis.
Parisi A, Giampieri R, Mammarella A, Felicetti C, Salvatore L, Bensi M, Maratta MG, Strippoli A, Filippi R, Satolli MA, Petrillo A, Daniele B, De Tursi M, Di Marino P, Giordano G, Landriscina M, Vitale P, Zurlo IV, Dell'Aquila E, Tomao S, Depetris I, Di Pietro FR, Zoratto F, Ciardiello D, Pensieri MV, Garrone O, Galassi B, Ferri C, Berardi R, Ghidini M. Parisi A, et al. Among authors: galassi b. Front Oncol. 2022 Aug 12;12:935826. doi: 10.3389/fonc.2022.935826. eCollection 2022. Front Oncol. 2022. PMID: 36033477 Free PMC article.
23 results